• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

犬体内血管紧张素I转换酶抑制剂(SA - 446)的肾脏排泄情况。

Renal excretion of an angiotensin I converting enzyme inhibitor (SA-446) in dogs.

作者信息

Abe Y, Okahara T, Miura K, Yukimura T, Takada T, Iwatani T, Iso T, Yamamoto K

出版信息

Naunyn Schmiedebergs Arch Pharmacol. 1984 Apr;325(4):356-9. doi: 10.1007/BF00504381.

DOI:10.1007/BF00504381
PMID:6328337
Abstract

The renal excretory mechanism of an orally active inhibitor of angiotensin converting enzyme (SA-446) was examined in anesthetized dogs. Parenteral administration of this compound resulted in production of constant levels of about 2 mg/l in the plasma (PSA) and the urine concentration was 726 +/- 200 mg/l, a level significantly higher than that in the plasma. Renal clearance of SA-446 (CSA) was 2.24 +/- 0.34 ml/g X min and was significantly higher than GFR. The clearance ratio (CSA/GFR) of over 1.0 was indicative of a net tubular secretion. Administration of probenecid resulted in a significant rise in PSA and in a significant decrease in urinary excretion but with no change in the plasma protein binding ratio. CSA decreased significantly from 2.24 +/- 0.34 to 0.71 +/- 0.14 ml/g X min. The inhibitory action of SA-446 (0.02 mg/kg, i.v.) on the pressor response to angiotensin I disappeared at about 50 min, this action being maintained for about 2 h in the probenecid pretreated dog. Since probenecid is a competitive inhibitor of organic anion secretory transport, our results show the net tubular secretion of SA-446, via organic anion transport systems. Prolongation of the action of SA-446, as induced by probenecid may be due to the increase of plasma concentration, by the inhibition of tubular secretion.

摘要

在麻醉犬身上研究了口服活性血管紧张素转换酶抑制剂(SA - 446)的肾脏排泄机制。静脉注射该化合物后,血浆中该化合物水平维持在约2mg/l恒定,尿浓度为726±200mg/l,显著高于血浆浓度。SA - 446的肾清除率(CSA)为2.24±0.34ml/g×min,显著高于肾小球滤过率(GFR)。清除率比值(CSA/GFR)大于1.0表明存在肾小管净分泌。给予丙磺舒后,血浆中SA - 446水平显著升高,尿排泄显著减少,但血浆蛋白结合率无变化。CSA从2.24±0.34显著降至0.71±0.14ml/g×min。静脉注射SA - 446(0.02mg/kg)对血管紧张素I升压反应的抑制作用在约50分钟时消失,而在丙磺舒预处理的犬中,该作用维持约2小时。由于丙磺舒是有机阴离子分泌转运的竞争性抑制剂,我们的结果表明SA - 446通过有机阴离子转运系统进行肾小管净分泌。丙磺舒诱导的SA - 446作用延长可能是由于肾小管分泌受抑制导致血浆浓度升高所致。

相似文献

1
Renal excretion of an angiotensin I converting enzyme inhibitor (SA-446) in dogs.犬体内血管紧张素I转换酶抑制剂(SA - 446)的肾脏排泄情况。
Naunyn Schmiedebergs Arch Pharmacol. 1984 Apr;325(4):356-9. doi: 10.1007/BF00504381.
2
Effects of angiotensin I-converting enzyme inhibitor (SA-446) on renal function in dogs.血管紧张素I转换酶抑制剂(SA - 446)对犬肾功能的影响。
Jpn J Pharmacol. 1985 Jun;38(2):227-30. doi: 10.1254/jjp.38.227.
3
Effect of SA-446, an angiotensin-converting enzyme inhibitor, on renal function in anesthetized dogs: special reference to arachidonic acid metabolites.血管紧张素转换酶抑制剂SA - 446对麻醉犬肾功能的影响:特别提及花生四烯酸代谢产物。
J Cardiovasc Pharmacol. 1985 Jan-Feb;7(1):102-7. doi: 10.1097/00005344-198501000-00017.
4
Studies on mechanisms of antinephritic action of SA-446 an angiotensin I converting enzyme inhibitor (1). A comparison with actions of spironolactone, kallidinogenase and saralasin.血管紧张素I转换酶抑制剂SA - 446抗肾炎作用机制的研究(1)。与螺内酯、激肽释放酶原酶和沙拉新作用的比较。
Jpn J Pharmacol. 1986 Dec;42(4):465-75. doi: 10.1254/jjp.42.465.
5
Effects of an orally active converting enzyme inhibitor (YS-980) on renal function in dogs.
J Pharmacol Exp Ther. 1980 Jul;214(1):166-70.
6
Hypotensive effect of SA446, an angiotensin converting enzyme inhibitor, in 2-kidney, 1-clip renal hypertensive and normotensive dogs.
Jpn J Pharmacol. 1987 Apr;43(4):379-87. doi: 10.1254/jjp.43.379.
7
A comparison of inhibition of angiotensin I conversion by three converting enzyme inhibitors in rats.三种转化酶抑制剂对大鼠血管紧张素I转化抑制作用的比较。
Clin Exp Pharmacol Physiol Suppl. 1982;7:129-34.
8
General pharmacological properties of the potent angiotensin converting enzyme inhibitor rentiapril.
Arzneimittelforschung. 1987 Feb;37(2):157-64.
9
Species difference of (2R,4R)-2-(o-hydroxyphenyl)-3-(3-mercaptopropionyl)-4-thiazolidinec arb oxylic acid (SA446) in inhibition of angiotensin converting enzyme.(2R,4R)-2-(邻羟基苯基)-3-(3-巯基丙酰基)-4-噻唑烷羧酸(SA446)在抑制血管紧张素转换酶方面的种属差异
Jpn J Pharmacol. 1986 Mar;40(3):367-72. doi: 10.1254/jjp.40.367.
10
In vivo comparison of three orally active inhibitors of angiotensin-converting enzyme.
Am J Cardiol. 1982 Apr 21;49(6):1502-4. doi: 10.1016/0002-9149(82)90368-x.

本文引用的文献

1
'Benemid,' p-(di-n-propylsulfamyl)-benzoic acid; its renal affinity and its elimination.“丙磺舒”,对-(二正丙基氨磺酰基)苯甲酸;其对肾脏的亲和力及其排泄。
Am J Physiol. 1951 Sep;166(3):625-40. doi: 10.1152/ajplegacy.1951.166.3.625.
2
RENAL TUBULAR MECHANISMS FOR EXCRETION OF ORGANIC ACIDS AND BASES.有机酸和碱排泄的肾小管机制
Am J Med. 1964 May;36:743-62. doi: 10.1016/0002-9343(64)90183-4.
3
Synthesis and antihypertensive activity of N-(mercaptoacyl)-thiazolidinecarboxylic acids.N-(巯基酰基)-噻唑烷羧酸的合成及其降压活性
Chem Pharm Bull (Tokyo). 1982 Feb;30(2):440-61. doi: 10.1248/cpb.30.440.
4
Renal handling of captopril: effect of probenecid.卡托普利的肾脏处理:丙磺舒的影响。
Clin Pharmacol Ther. 1982 Aug;32(2):182-9. doi: 10.1038/clpt.1982.145.
5
Disposition of captopril in normal subjects.卡托普利在正常受试者体内的处置情况。
Clin Pharmacol Ther. 1980 May;27(5):636-41. doi: 10.1038/clpt.1980.90.
6
The pharmacological role of the kidney.肾脏的药理学作用。
Drugs. 1980 Jan;19(1):31-48. doi: 10.2165/00003495-198019010-00003.
7
Determination of SA-446 in human whole blood and urine by electron capture-gas liquid chromatography.用电子捕获-气液色谱法测定人全血和尿液中的SA - 446。
Chem Pharm Bull (Tokyo). 1982 Jun;30(6):2087-93. doi: 10.1248/cpb.30.2087.
8
Inhibitor of angiotensin I converting enzyme: (4R)-3-[(2S)-3-mercapto-2-methylpropanoyl]-4-thiazolidinecarboxylic acid (YS-980).
Biochem Pharmacol. 1980 Jun 1;29(11):1543-7. doi: 10.1016/0006-2952(80)90606-1.
9
A new potent inhibitor of converting enzyme: (2R,4R)-2-(2-hydroxyphenyl)-3-(3-mercaptopropionyl)-4-thiazolidinecarboxylic acid(SA446).
Jpn J Pharmacol. 1981 Dec;31(6):875-82. doi: 10.1254/jjp.31.875.
10
Effects of an orally active converting enzyme inhibitor (YS-980) on renal function in dogs.
J Pharmacol Exp Ther. 1980 Jul;214(1):166-70.